Loading
A phase 3 trial of Sacituzumab tirumotecan, Bevacizumab, Dexamethasone in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) is a phase 3 interventional study registered as NCT06824467 by Merck Sharp & Dohme LLC, with 770 participants planned, started 2025-04-09 and due to reach its primary completion in 2029-04-27. Interventions recorded: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent). Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Bevacizumab, Anti-angiogenic therapy, Topoisomerase-I inhibitors (and ADC payloads).
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Sacituzumab tirumotecan, Bevacizumab, Anti-angiogenic therapy, Topoisomerase-I inhibitors (and ADC payloads).
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Sacituzumab tirumotecan, Dexamethasone, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).